

# Els Van Nieuwenhuysen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/206551/publications.pdf>

Version: 2024-02-01

38  
papers

1,555  
citations

430874

18  
h-index

330143

37  
g-index

41  
all docs

41  
docs citations

41  
times ranked

3630  
citing authors

#	ARTICLE	IF	CITATIONS
1	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	2.8	23
2	Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 753-760.	2.5	3
3	Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 14-22.	1.4	14
4	Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5517-5517.	1.6	2
5	Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB&IIB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 824-828.	2.5	6
6	High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. <i>Genome Medicine</i> , 2021, 13, 111.	8.2	70
7	Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria. <i>Gynecologic Oncology</i> , 2021, 162, 539-545.	1.4	7
8	Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study. <i>Gynecologic Oncology</i> , 2021, 162, 694-701.	1.4	9
9	Experience with PlasmaJet&reg; in debulking surgery in 87 patients with advanced&stage ovarian cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1109-1114.	1.7	6
10	Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1041-1048.	2.5	1
11	Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. <i>Gynecologic Oncology</i> , 2020, 156, 308-314.	1.4	32
12	Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D. <i>Gynecologic Oncology</i> , 2020, 157, 245-251.	1.4	24
13	Decentralization of Next-Generation RNA Sequencing-Based MammaPrint&reg; and Blueprint&reg; Kit at University Hospitals Leuven and Curie Institute Paris. <i>Translational Oncology</i> , 2019, 12, 1557-1565.	3.7	6
14	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	12.8	88
15	Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer. <i>Neoplasia</i> , 2019, 21, 582-590.	5.3	24
16	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , 2019, 8, 2503-2513.	2.8	6
17	The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. <i>European Journal of Epidemiology</i> , 2019, 34, 591-600.	5.7	16
18	EP877&reg;...Intestinal (sub)obstruction in ovarian cancer patients: management, complications and survival. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129.	6.4	15
20	The genetic landscape of 87 ovarian germ cell tumors. <i>Gynecologic Oncology</i> , 2018, 151, 61-68.	1.4	44
21	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	4.1	3
22	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
23	Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. <i>BMC Medicine</i> , 2017, 15, 116.	5.5	44
24	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424.	2.5	3
25	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.	1.9	71
26	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	3.8	19
27	Ovarian cancer in children and adolescents: A rare disease that needs more attention. <i>Maturitas</i> , 2016, 88, 3-8.	2.4	19
28	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	1.9	111
29	The role of HE4 for prediction of recurrence in epithelial ovarian cancer patientsâ€”results from the OVCAD study. <i>Tumor Biology</i> , 2016, 37, 3009-3016.	1.8	23
30	Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 6353-6368.	1.8	29
31	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	21.4	221
32	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584.	2.5	28
33	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.	1.4	15
34	Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. <i>BMC Pharmacology &amp; Toxicology</i> , 2015, 16, 2.	2.4	33
35	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015, 6, 8234.	12.8	63
36	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.	2.8	24

#	ARTICLE	IF	CITATIONS
37	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	2.9	68
38	Genetic changes in nonepithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 871-882.	2.4	16